{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T06:56:31Z","timestamp":1767164191271,"version":"build-2238731810"},"reference-count":44,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1124\/dmd.118.083907","type":"journal-article","created":{"date-parts":[[2018,11,30]],"date-time":"2018-11-30T14:25:13Z","timestamp":1543587913000},"page":"155-163","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Altered Hepatobiliary Disposition of Tolvaptan and Selected Tolvaptan Metabolites in a Rodent Model of Polycystic Kidney Disease"],"prefix":"10.1016","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6926-8844","authenticated-orcid":false,"given":"James J.","family":"Beaudoin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacqueline","family":"Bezen\u00e7on","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanguang","family":"Cao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katsuhiko","family":"Mizuno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sharin E.","family":"Roth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William J.","family":"Brock","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1945-4929","authenticated-orcid":false,"given":"Kim L.R.","family":"Brouwer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1124\/dmd.118.083907_bib1","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1023\/A:1012299115260","article-title":"Ways to fit a PK model with some data below the quantification limit","volume":"28","author":"Beal","year":"2001","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"10.1124\/dmd.118.083907_bib2","first-page":"3641","article-title":"Effect of multidrug resistance modulators on the hepatobiliary disposition of doxorubicin in the isolated perfused rat liver","volume":"58","author":"Booth","year":"1998","journal-title":"Cancer Res"},{"key":"10.1124\/dmd.118.083907_bib3","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1177\/1091581818760746","article-title":"Bile acids as potential biomarkers to assess liver impairment in polycystic kidney disease","volume":"37","author":"Brock","year":"2018","journal-title":"Int J Toxicol"},{"key":"10.1124\/dmd.118.083907_bib4","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/978-1-4899-1863-5_10","article-title":"Isolated perfused liver","volume":"8","author":"Brouwer","year":"1996","journal-title":"Pharm Biotechnol"},{"key":"10.1124\/dmd.118.083907_bib5","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1124\/dmd.105.003665","article-title":"Modulation of hepatic canalicular or basolateral transport proteins alters hepatobiliary disposition of a model organic anion in the isolated perfused rat liver","volume":"33","author":"Chandra","year":"2005","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.118.083907_bib6","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.tiv.2013.10.020","article-title":"Toxicity and intracellular accumulation of bile acids in sandwich-cultured rat hepatocytes: role of glycine conjugates","volume":"28","author":"Chatterjee","year":"2014","journal-title":"Toxicol In Vitro"},{"key":"10.1124\/dmd.118.083907_bib7","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/1750-1172-9-69","article-title":"Polycystic liver disease: an overview of pathogenesis, clinical manifestations and management","volume":"9","author":"Cnossen","year":"2014","journal-title":"Orphanet J Rare Dis"},{"key":"10.1124\/dmd.118.083907_bib8","doi-asserted-by":"crossref","first-page":"410","DOI":"10.2353\/ajpath.2006.050404","article-title":"Lithocholic acid feeding induces segmental bile duct obstruction and destructive cholangitis in mice","volume":"168","author":"Fickert","year":"2006","journal-title":"Am J Pathol"},{"key":"10.1124\/dmd.118.083907_bib9","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1007\/s12272-014-0352-2","article-title":"Liquid chromatography-tandem mass spectrometry method for determining tolvaptan and its nine metabolites in rat serum: application to a pharmacokinetic study","volume":"37","author":"Furukawa","year":"2014","journal-title":"Arch Pharm Res"},{"key":"10.1124\/dmd.118.083907_bib10","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1002\/hep.1840120307","article-title":"Ursodeoxycholate reduces hepatotoxicity of bile salts in primary human hepatocytes","volume":"12","author":"Galle","year":"1990","journal-title":"Hepatology"},{"key":"10.1124\/dmd.118.083907_bib11","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1056\/NEJMcp0804458","article-title":"Clinical practice. Autosomal dominant polycystic kidney disease","volume":"359","author":"Grantham","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1124\/dmd.118.083907_bib12","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1038\/nrneph.2011.109","article-title":"Why kidneys fail in autosomal dominant polycystic kidney disease","volume":"7","author":"Grantham","year":"2011","journal-title":"Nat Rev Nephrol"},{"key":"10.1124\/dmd.118.083907_bib44","unstructured":"Guide for the Care and Use of Laboratory Animals. National Research Council (US) Committee for the Update of the Guide for the Care and Use of Laboratory Animals. 8th edition. Washington (DC): National Academies Press (US); 2011. ISBN 978-0-309-38629-6 | DOI 10.17226\/12910"},{"key":"10.1124\/dmd.118.083907_bib13","doi-asserted-by":"crossref","first-page":"327","DOI":"10.3109\/00498254.2011.625452","article-title":"Understanding the interplay of drug transporters involved in the disposition of rosuvastatin in the isolated perfused rat liver using a physiologically-based pharmacokinetic model","volume":"42","author":"Hobbs","year":"2012","journal-title":"Xenobiotica"},{"key":"10.1124\/dmd.118.083907_bib14","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1681\/ASN.2007030299","article-title":"Polycystic kidney disease","volume":"18","author":"Igarashi","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"10.1124\/dmd.118.083907_bib15","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.jchromb.2016.03.032","article-title":"A rapid and sensitive LC-MS\/MS-ESI method for the determination of tolvaptan and its two main metabolites in human plasma","volume":"1027","author":"Jiang","year":"2016","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"10.1124\/dmd.118.083907_bib16","doi-asserted-by":"crossref","first-page":"2628","DOI":"10.1007\/s11095-012-0805-6","article-title":"Use of pharmacokinetic data below lower limit of quantitation values","volume":"29","author":"Jusko","year":"2012","journal-title":"Pharm Res"},{"key":"10.1124\/dmd.118.083907_bib17","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1681\/ASN.2008010033","article-title":"ARPKD and ADPKD: first cousins or more distant relatives?","volume":"19","author":"Kaimori","year":"2008","journal-title":"J Am Soc Nephrol"},{"key":"10.1124\/dmd.118.083907_bib18","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1538\/expanim.49.51","article-title":"Characterization of a novel polycystic kidney rat model with accompanying polycystic liver","volume":"49","author":"Katsuyama","year":"2000","journal-title":"Exp Anim"},{"key":"10.1124\/dmd.118.083907_bib19","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1681\/ASN.2007070770","article-title":"Fibrocystin\/polyductin modulates renal tubular formation by regulating polycystin-2 expression and function","volume":"19","author":"Kim","year":"2008","journal-title":"J Am Soc Nephrol"},{"key":"10.1124\/dmd.118.083907_bib20","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1046\/j.1523-1755.2001.00473.x","article-title":"The PCK rat: a new model that resembles human autosomal dominant polycystic kidney and liver disease","volume":"59","author":"Lager","year":"2001","journal-title":"Kidney Int"},{"key":"10.1124\/dmd.118.083907_bib21","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1124\/dmd.115.067629","article-title":"Hepatocellular disposition and transporter interactions with tolvaptan and metabolites in sandwich-cultured human hepatocytes","volume":"44","author":"Lu","year":"2016","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.118.083907_bib22","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1016\/S0002-9440(10)63427-X","article-title":"Biliary dysgenesis in the PCK rat, an orthologous model of autosomal recessive polycystic kidney disease","volume":"165","author":"Masyuk","year":"2004","journal-title":"Am J Pathol"},{"key":"10.1124\/dmd.118.083907_bib23","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.jpba.2017.06.054","article-title":"Characterization of the phase I and phase II metabolic profile of tolvaptan by in vitro studies and liquid chromatography-mass spectrometry profiling: relevance to doping control analysis","volume":"145","author":"Mazzarino","year":"2017","journal-title":"J Pharm Biomed Anal"},{"key":"10.1124\/dmd.118.083907_bib24","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1124\/dmd.108.021790","article-title":"Hepatic metabolism and biliary excretion of silymarin flavonolignans in isolated perfused rat livers: role of multidrug resistance-associated protein 2 (Abcc2)","volume":"36","author":"Miranda","year":"2008","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.118.083907_bib25","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/j.jhep.2015.05.023","article-title":"Ursodeoxycholic acid inhibits hepatic cystogenesis in experimental models of polycystic liver disease","volume":"63","author":"Munoz-Garrido","year":"2015","journal-title":"J Hepatol"},{"key":"10.1124\/dmd.118.083907_bib26","first-page":"625","article-title":"Hepatic clearance of drugs. I. Theoretical considerations of a \u201cwell-stirred\u201d model and a \u201cparallel tube\u201d model","volume":"5","author":"Pang","year":"1977","journal-title":"Influence of hepatic blood flow, plasma and blood cell binding, and the hepatocellular enzymatic activity on hepatic drug clearance. J Pharmacokinet Biopharm"},{"key":"10.1124\/dmd.118.083907_bib27","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1007\/BF01059689","article-title":"Hepatic clearance of drugs. II. Experimental evidence for acceptance of the \u201cwell-stirred\u201d model over the \u201cparallel tube\u201d model using lidocaine in the perfused rat liver in situ preparation","volume":"5","author":"Pang","year":"1977","journal-title":"J Pharmacokinet Biopharm"},{"key":"10.1124\/dmd.118.083907_bib28","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1007\/BF01059690","volume":"5","author":"Pang","year":"1977","journal-title":"J Pharmacokinet Biopharm"},{"key":"10.1124\/dmd.118.083907_bib29","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1124\/jpet.113.208314","article-title":"Hepatic basolateral efflux contributes significantly to rosuvastatin disposition II: characterization of hepatic elimination by basolateral, biliary, and metabolic clearance pathways in rat isolated perfused liver","volume":"347","author":"Pfeifer","year":"2013","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.118.083907_bib30","series-title":"Cell Separation: Methods and Selected Applications","first-page":"1","author":"Pretlow","year":"1987"},{"key":"10.1124\/dmd.118.083907_bib31","doi-asserted-by":"crossref","first-page":"F1243","DOI":"10.1152\/ajprenal.00694.2013","article-title":"Effects of combined administration of rapamycin, tolvaptan, and AEZ-131 on the progression of polycystic disease in PCK rats","volume":"306","author":"Sabbatini","year":"2014","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1124\/dmd.118.083907_bib32","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1198\/000313001317097960","article-title":"On judging the significance of differences by examining the overlap between confidence intervals","volume":"55","author":"Schenker","year":"2001","journal-title":"Am Stat"},{"key":"10.1124\/dmd.118.083907_bib33","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1177\/1091581815611075","article-title":"Age-related alterations in blood biochemical characterization of hepatorenal function in the PCK rat: a model of polycystic kidney disease","volume":"34","author":"Shimomura","year":"2015","journal-title":"Int J Toxicol"},{"key":"10.1124\/dmd.118.083907_bib34","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1177\/0091270010376193","article-title":"In vitro P-glycoprotein interactions and steady-state pharmacokinetic interactions between tolvaptan and digoxin in healthy subjects","volume":"51","author":"Shoaf","year":"2011","journal-title":"J Clin Pharmacol"},{"key":"10.1124\/dmd.118.083907_bib35","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1093\/toxsci\/kfv231","article-title":"Inhibition of human hepatic bile acid transporters by tolvaptan and metabolites: contributing factors to drug-induced liver injury?","volume":"149","author":"Slizgi","year":"2016","journal-title":"Toxicol Sci"},{"key":"10.1124\/dmd.118.083907_bib36","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1358\/dof.2002.027.04.668950","article-title":"Tolvaptan: treatment for heart failure vasopressin V2 antagonist","volume":"27","author":"Sorbera","year":"2002","journal-title":"Drugs Future"},{"key":"10.1124\/dmd.118.083907_bib37","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1056\/NEJMoa1205511","article-title":"Tolvaptan in patients with autosomal dominant polycystic kidney disease","volume":"367","author":"Torres","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1124\/dmd.118.083907_bib38","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1056\/NEJMoa1710030","article-title":"Tolvaptan in later-stage autosomal dominant polycystic kidney disease","volume":"377","author":"Torres","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1124\/dmd.118.083907_bib39","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/S0140-6736(07)60601-1","article-title":"Autosomal dominant polycystic kidney disease","volume":"369","author":"Torres","year":"2007","journal-title":"Lancet"},{"key":"10.1124\/dmd.118.083907_bib40","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1124\/jpet.108.146647","article-title":"Physiologically based pharmacokinetic modeling to predict transporter-mediated clearance and distribution of pravastatin in humans","volume":"328","author":"Watanabe","year":"2009","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.118.083907_bib41","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1007\/s40264-015-0327-3","article-title":"Clinical pattern of tolvaptan-associated liver injury in subjects with autosomal dominant polycystic kidney disease: analysis of clinical trials database","volume":"38","author":"Watkins","year":"2015","journal-title":"Drug Saf"},{"key":"10.1124\/dmd.118.083907_bib42","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/S0022-3565(24)38933-5","article-title":"Altered hepatobiliary disposition of acetaminophen glucuronide in isolated perfused livers from multidrug resistance-associated protein 2-deficient TR\u2212 rats","volume":"295","author":"Xiong","year":"2000","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.118.083907_bib43","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.taap.2016.06.019","article-title":"Dioscin protects against ANIT-induced cholestasis via regulating Oatps, Mrp2 and Bsep expression in rats","volume":"305","author":"Zhang","year":"2016","journal-title":"Toxicol Appl Pharmacol"}],"updated-by":[{"DOI":"10.1124\/dmd.115.083907err","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000}}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624079972?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624079972?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/dmd.118.083907","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T14:01:07Z","timestamp":1739887267000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955624079972"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2]]},"references-count":44,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["S0090955624079972"],"URL":"https:\/\/doi.org\/10.1124\/dmd.118.083907","relation":{},"ISSN":["0090-9556"],"issn-type":[{"value":"0090-9556","type":"print"}],"subject":[],"published":{"date-parts":[[2019,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Altered Hepatobiliary Disposition of Tolvaptan and Selected Tolvaptan Metabolites in a Rodent Model of Polycystic Kidney Disease","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/dmd.118.083907","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}